Journal
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
Volume 49, Issue 4, Pages 689-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.gtc.2020.07.002
Keywords
Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Chronic disorder; Dibutyl phthalate; Therapy; Endoscopic healing
Categories
Ask authors/readers for more resources
Inflammatory bowel disease is a chronic disorder of intestinal inflammation and includes Crohn's disease and ulcerative colitis. The goal of therapy is to induce and maintain remission, which is achieved with conventional therapies. Mesalamine is considered a first-line therapy for ulcerative colitis. Clinical trials have confirmed its efficacy and safety in patients with mild to moderate ulcerative colitis. Doses of more than 2.4 g/d achieve significantly higher rates of clinical and endoscopic remission, with a decreased risk of relapse. Serious adverse effects are rare, but nonadherence is common. Mesalamine is considered safe in pregnancy, excluding formulations with dibutyl phthalate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available